ClinicalTrials.gg
CompletedNCT01475786Updated Oct 6, 2025Results posted

Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

A Phase 2 interventional study of Low Dose: 16 mg Engensis (VM202) and High Dose: 32 mg Engensis (VM202) in Painful Diabetic Neuropathies, sponsored by Helixmith Co., Ltd.. Completed at 17 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-06.

Sponsored by Helixmith Co., Ltd. · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to determine if Engensis (VM202) is safe and effective in treating painful diabetic neuropathy.

Read the detailed description

Peripheral neuropathy is a serious complication of diabetes. This form of neuropathy carries a high risk of pain, trophic changes and autonomic dysfunction. There is currently no effective treatment for diabetic neuropathy, and good glycemic control is the only way to minimize the risk of occurrence. Clearly, it would be desirable to prevent, impede, or reverse the disrupting and often life-threatening manifestations of peripheral neuropathy by stimulating growth or regeneration of peripheral nerve axons.

02

Conditions studied

  • Painful Diabetic Neuropathies

Keywords

  • nerve pain
  • diabetic nerve pain
  • throbbing
  • burning
  • painful feet
  • tingling
  • numbness
  • Engensis (VM202)
03

In context

Diabetic Neuropathies

538 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

This study's enrollment of 104 is above the median of 68 across 448 interventional studies indexed under Diabetic Neuropathies.

Browse Diabetic Neuropathies studies →

Lead sponsor

Helixmith Co., Ltd. is the lead sponsor of 19 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years to ≤ 75 years
  • Documented history of Type I or II diabetes with current treatment control (glycosylated of ≤ 10.0% at Screening) and currently on oral medication and/or insulin
  • Diagnosis of painful diabetic peripheral neuropathy in both lower extremities
  • Lower extremity pain for at least 6 months
  • Visual analog scale (VAS) score of ≥ 40 mm at Initial Screening (0 mm = no pain - 100 mm very severe pain)
  • Symptoms from the Brief Pain Neuropathy Screening (BPNS) is ≤ 5 point difference between legs at Initial Screening
  • The average daily pain intensity score of the Daily Pain and Sleep Interference Diary completed after medication wash-out is ≥ 4 with a standard deviation ≤ 2
  • The physical examination component of the Michigan Neuropathy Screening Instrument Score (MNSI) is ≥ 3 at Screening
  • Stable treatment of diabetes for at least 3 months with no anticipated changes in medication regimen, and no new symptoms associated with diabetes
  • If female of , negative urine pregnancy test at screening and using acceptable method of during the study

Exclusion criteria

Exclusion Criteria:

  • Peripheral neuropathy caused by condition other than diabetes
  • Other pain more severe than neuropathic pain
  • Progressive or degenerative neurological disorder
  • Myopathy
  • Inflammatory disorder of the blood vessels (inflammatory angiopathy, such as Buerger's disease)
  • Active infection
  • Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis)
  • Positive or HTLV at Screening
  • Active or C as determined by Hepatitis B core antibody (HBcAB), antibody to Hepatitis B antigen (IgG and IgM; HbsAb), Hepatitis B surface antigen (HBsAg) and antibodies (Anti-HCV) at Screening
  • Subjects with known or currently receiving immunosuppressive drugs, chemotherapy or radiation therapy
  • Stroke or myocardial infarction within last 3 months
  • Ophthalmologic conditions pertinent to proliferative retinopathy or conditions that preclude standard ophthalmologic examination
  • Specific laboratory values at Screening including: \< 8.0 g/dL, WBC \< 3,000 cells per microliter, count \<75,000/mm3, Creatinine > 2.0 mg/dL; and/or ALT > 3 times the or any other lab abnormality which in the opinion of the investigator should be exclusionary
  • Uncontrolled hypertension as defined as sustained systolic blood pressure (SBP) > 200 mmHg or diastolic BP (DBP) > 110 mmHg at Screening
  • Patients with a recent history (\< 5 years) of or new screening finding of malignant neoplasm except basal cell carcinoma or squamous cell carcinoma of the skin (if excised and no evidence of recurrence); patients with family history of colon cancer in any first degree relative are excluded unless they have undergone a colonoscopy in the last 12 months with negative findings
  • Subjects requiring > 81 mg daily of acetylsalicylic acid; If ≥ 81 mg are taken at screening, subjects may be enrolled if willing/able to switch to another medication
  • Use of any opioids; subjects may be enrolled if willing and able to discontinue use of these drugs 14 days prior to starting the 7 Day Daily Pain and Sleep Interference Diary and refrain from taking these drugs for the duration of the study
  • Subjects requiring regular COX-2 inhibitor drug(s) or non-specific COX-1/COX-2 inhibiting drugs, or high dose (excepting inhaled steroids).Subjects may be enrolled if willing/able to undergo medication prior to the first dosing and to refrain from taking these drugs for the duration of the study;
  • Major psychiatric disorder in within last 6 months
  • (BMI) > 45 kg/m2 at Screening
  • Any lower extremity amputation
  • Use of an drug or treatment in past 6 months
  • Unable or unwilling to give
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
104 participants (actual)

Study arms

  • Active comparator
    Low Dose 16mg Engensis (VM202) and Placebo

    intramuscular injections in each calf for a total of 16mg Engensis (VM202): Day 0 - 32 injections / calf 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf) and 16 injections of normal saline 0.5mL / calf Day 14 - 32 injections / calf and 16 injections of normal saline 0.5mL / calf 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)

    Biological: Low Dose: 16 mg Engensis (VM202) · Other: Control- Placebo (normal saline)

  • Active comparator
    High Dose 32mg Engensis (VM202)

    Day 0 - 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) Day 14 - 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) For a total of 32mg VM202

    Biological: High Dose: 32 mg Engensis (VM202)

  • Placebo comparator
    Control - Placebo (normal saline)

    32 injections / calf of 0.5 mL normal saline at Day 0 and Day 14

    Other: Control- Placebo (normal saline)

Interventions

  • Subjects in the Low Dose Group (8mg VM202 / leg) will receive the following intramuscular injections in each calf: Day 0 - 32 injections / calf: • 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf) Day 14 - 32 injections / calf: • 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)

    Also known as: Gene Therapy

  • Subjects in the High Dose Group (16 mg VM202 / leg) will receive the following intramuscular injections in each calf: Day 0 • 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) Day 14 • 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)

    Also known as: Gene Therapy

  • OtherControl- Placebo (normal saline)

    subjects will receive thirty-two (32) 0.5 mL injections of normal saline on Day 0 and Day 14.

    Also known as: Normal saline

06

What researchers measure

Primary outcomes

  1. The Primary Study Endpoint Was the Change in Average 24-hour Pain Score From Baseline to the 6-month Follow-up.

    The difference in the mean change of the 24 hour pain score was compared between the treatment groups and the placebo arm to determine treatment effect. The average pain scores were obtained from the Daily Pain and Sleep Interference Diary (recorded daily by subjects for 7 days during Screening prior to the first round of injections and again, before the 6 month follow-up). Subjects rated their 24-hor daily pain intensity according to the 11-point numerical rating scale from 0 (no pain) to 10 (worst possible pain).

    Time frame: seven (7) days before 9 Month visit

07

Results

Posted Jul 3, 2023

Participant flow

Participant flow — Overall Study
MilestoneHigh Dose 32mg Engensis (VM202)Low Dose 16mg Engensis (VM202) and PlaceboControl - Placebo (Normal Saline)
Started434021
Completed413619
Not completed242
Withdrew: Adverse event010
Withdrew: Lost to follow-up121
Withdrew: Withdrawal by subject011
Withdrew: Subject discontinued prior to study treatment100

Outcome measures

PrimaryThe Primary Study Endpoint Was the Change in Average 24-hour Pain Score From Baseline to the 6-month Follow-up.

The difference in the mean change of the 24 hour pain score was compared between the treatment groups and the placebo arm to determine treatment effect. The average pain scores were obtained from the Daily Pain and Sleep Interference Diary (recorded daily by subjects for 7 days during Screening prior to the first round of injections and again, before the 6 month follow-up). Subjects rated their 24-hor daily pain intensity according to the 11-point numerical rating scale from 0 (no pain) to 10 (worst possible pain).

Time frame:
seven (7) days before 9 Month visit
Reported as:
Mean · units on a scale
The Primary Study Endpoint Was the Change in Average 24-hour Pain Score From Baseline to the 6-month Follow-up.
units on a scaleHigh Dose 32mg Engensis (VM202)Low Dose 16mg Engensis (VM202) and PlaceboControl - Placebo (Normal Saline)
The Primary Study Endpoint Was the Change in Average 24-hour Pain Score From Baseline to the 6-month Follow-up.-1.94 ± 1.96-2.78 ± 2.23-1.59 ± 1.89

Adverse events

Collected over Baseline (Day 0) to Day 270. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
High Dose 32mg Engensis (VM202)0/43 (0%)4/43 (9.3%)33/43 (76.7%)
Low Dose 16mg Engensis (VM202) and Placebo0/39 (0%)3/39 (7.7%)22/39 (56.4%)
Control - Placebo (Normal Saline)0/21 (0%)3/21 (14.3%)13/21 (61.9%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventHigh Dose 32mg Engensis (VM202)Low Dose 16mg Engensis (VM202) and PlaceboControl - Placebo (Normal Saline)
GastroenteritisInfections and infestations0/430/391/21
Localised infectionInfections and infestations0/430/391/21
PneumoniaInfections and infestations0/430/391/21
Rib fractureInjury, poisoning and procedural complications0/430/391/21
Drug abusePsychiatric disorders0/430/391/21
Omental infarctionGastrointestinal disorders0/431/390/21
CholecystitisHepatobiliary disorders0/431/390/21
HyperglycaemiaMetabolism and nutrition disorders0/431/390/21
Left ventricular dysfunctionCardiac disorders1/430/390/21
Chest painGeneral disorders1/430/390/21
Most frequent other events
Showing 10 of 19
Most frequent other events
EventHigh Dose 32mg Engensis (VM202)Low Dose 16mg Engensis (VM202) and PlaceboControl - Placebo (Normal Saline)
DiarrhoeaGastrointestinal disorders1/430/393/21
SinusitisInfections and infestations0/435/390/21
Upper respiratory tract infectionInfections and infestations1/431/392/21
BronchitisInfections and infestations0/431/392/21
PneumoniaInfections and infestations1/430/392/21
Ligament sprainMusculoskeletal and connective tissue disorders0/432/392/21
Localised infectionInfections and infestations4/433/391/21
Pain in extremityMusculoskeletal and connective tissue disorders4/431/391/21
NasopharyngitisInfections and infestations3/430/390/21
NauseaGastrointestinal disorders3/431/390/21

Baseline characteristics

Subjects in the intent to treat (ITT) population were those who were randomized and received study treatments

Age, Continuous
Age, Continuous(years)High Dose 32mg Engensis (VM202)Low Dose 16mg Engensis (VM202) and PlaceboControl - Placebo (Normal Saline)Total
Mean60.6 ± 10.260.2 ± 7.260.5 ± 8.360.4 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)High Dose 32mg Engensis (VM202)Low Dose 16mg Engensis (VM202) and PlaceboControl - Placebo (Normal Saline)Total
Female911626
Male33291577
Race (NIH/OMB)
Race (NIH/OMB)(Participants)High Dose 32mg Engensis (VM202)Low Dose 16mg Engensis (VM202) and PlaceboControl - Placebo (Normal Saline)Total
American Indian or Alaska Native1001
Asian65617
Native Hawaiian or Other Pacific Islander0000
Black or African American37212
White32271271
More than one race0101
Unknown or Not Reported0011
Region of Enrollment
Region of Enrollment(participants)High Dose 32mg Engensis (VM202)Low Dose 16mg Engensis (VM202) and PlaceboControl - Placebo (Normal Saline)Total
United States424021103
08

Study locations

17 sites
  • Diablo Clinical Research
    Walnut Creek, California 94598, United States
  • Compass Research
    Orlando, Florida 32806, United States
  • Palm Beach Neurological Center
    Palm Beach Gardens, Florida 33418, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Beth Israel Deaconess
    Boston, Massachusetts 02115, United States
  • The Neurosciences Institute Albany Medical College
    Albany, New York 12208, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • University of Oklahoma Harold Hamm Diabetes Center
    Oklahoma City, Oklahoma 73104, United States
  • Houston Neurocare
    Houston, Texas 77030, United States
  • The Methodist Hospital
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • East Virginia Medical School Strelitz Diabetes Center
    Norfolk, Virginia 23510, United States
  • Rainier Clinical Research
    Seattle, Washington 98057, United States
  • Seoul National University Bundang Hospital
    Seongnam, Bundang-gu 463-707, South Korea
  • Yonsei University College of Medicine Severance Hospital
    Seoul, Seodaemun-gu 120-752, South Korea
  • Sejong General Hospital
    Bucheon-si, Sosa-gu 422-711, South Korea
  • The Catholic University of Korea Youido St. Mary's Hospital
    Seoul, Yeongdeungpo-gu 150-713, South Korea
09

References and documents

Publications

  • Kessler JA, Smith AG, Cha BS, Choi SH, Wymer J, Shaibani A, Ajroud-Driss S, Vinik A; VM202 DPN-II Study Group. Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy. Ann Clin Transl Neurol. 2015 May;2(5):465-78. doi: 10.1002/acn3.186. Epub 2015 Mar 5. PubMed 26000320 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Mar 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2023, 9 years 3 months after primary completion. A results delay was requested in Dec 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2011
First posted
Nov 21, 2011
Start
Aug 2012
Primary completionActual
Mar 12, 2014
CompletionActual
Jun 2014
Results delay requested
Dec 7, 2015
Results first posted
Jul 3, 2023
Last update
Oct 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01475786
Lead sponsor
Helixmith Co., Ltd.
Responsible party
Sponsor
First posted
Nov 21, 2011
Start date
Aug 2012
Primary completion
Mar 12, 2014
Completion
Jun 2014
Results posted
Jul 3, 2023
Last update
Oct 6, 2025

Study contacts

Jack Kessler, MD
principal investigator · Northwestern University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donaperminogene seltoplasmid

Start the discussion